Literature DB >> 19436513

Case report and review of the literature: Toxoplasma gondii encephalitis in a 40-year-old woman with common variable immunodeficiency and a new diagnosis of large granular lymphocytic leukemia.

Adam Hofmann1, Gerasimos Zaharatos, Mark Miller.   

Abstract

Toxoplasma gondii has been well-documented to cause central nervous system infections in immunodeficient patients. The present study describes a case of central nervous system toxoplasmosis in a patient with common variable immunodeficiency and newly diagnosed large granular lymphocytic leukemia, with a review of the literature for this association.

Entities:  

Keywords:  Cerebral toxoplasmosis; Common variable immunodeficiency; Large granular lymphocytic leukemia; Toxoplasma gondii

Year:  2008        PMID： 19436513      PMCID： PMC2604779          DOI： 10.1155/2008/614279

Source DB:  PubMed          Journal:  Can J Infect Dis Med Microbiol        ISSN： 1712-9532            Impact factor:   2.471


  8 in total

Review 1.  Primary immunodeficiency diseases. Report of an IUIS Scientific Committee. International Union of Immunological Societies.

Authors: 
Journal:  Clin Exp Immunol       Date:  1999-10       Impact factor: 4.330

Review 2.  Host resistance in the brain against Toxoplasma gondii.

Authors:  Yasuhiro Suzuki
Journal:  J Infect Dis       Date:  2002-02-15       Impact factor: 5.226

3.  Cerebral toxoplasmosis in a patient with common variable immunodeficiency.

Authors:  Martin Holtkamp; Ali Fuat Okuducu; Randolf Klingebiel; Christoph J Ploner
Journal:  Neurology       Date:  2004-12-14       Impact factor: 9.910

4.  NK cells help to induce CD8(+)-T-cell immunity against Toxoplasma gondii in the absence of CD4(+) T cells.

Authors:  Crescent L Combe; Tyler J Curiel; Magali M Moretto; Imtiaz A Khan
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

5.  Decreased resistance of B cell-deficient mice to infection with Toxoplasma gondii despite unimpaired expression of IFN-gamma, TNF-alpha, and inducible nitric oxide synthase.

Authors:  H Kang; J S Remington; Y Suzuki
Journal:  J Immunol       Date:  2000-03-01       Impact factor: 5.422

Review 6.  Development of granulomatous common variable immunodeficiency subsequent to infection with Toxoplasma gondii.

Authors:  S Mrusek; A Marx; J Kummerle-Deschner; N Tzaribachev; A Enders; U-N Riede; K Warnatz; G E Dannecker; S Ehl
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

7.  Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome.

Authors:  S B Porter; M A Sande
Journal:  N Engl J Med       Date:  1992-12-03       Impact factor: 91.245

8.  Toxoplasmosis in a patient with common variable immunodeficiency.

Authors:  J Shachor; A Shneyour; J Radnay; Z P Steiner; I Bruderman
Journal:  Am J Med Sci       Date:  1984 May-Jun       Impact factor: 2.378
  8 in total
  4 in total

1.  Neurologic Complications of Common Variable Immunodeficiency.

Authors:  Jenna Thuc-Uyen Nguyen; Ari Green; Michael R Wilson; Joseph L DeRisi; Katherine Gundling
Journal:  J Clin Immunol       Date:  2016-10-04       Impact factor: 8.317

2.  Cerebral toxoplasmosis in a patient with combined variable immunodeficiency.

Authors:  Torrey Czech; Parthav Shah; Gunnar Lee; Gina Watanabe; Christian Ogasawara; Thomas Noh
Journal:  Surg Neurol Int       Date:  2022-08-12

3.  Testicular toxoplasmosis in a 26-year-old immunocompetent man.

Authors:  Vincent Wong; Channa Amarasekera; Shilajit Kundu
Journal:  BMJ Case Rep       Date:  2018-06-04

Review 4.  Disseminated and Congenital Toxoplasmosis in a Mother and Child With Activated PI3-Kinase δ Syndrome Type 2 (APDS2): Case Report and a Literature Review of Toxoplasma Infections in Primary Immunodeficiencies.

Authors:  Djuro Karanovic; Ian C Michelow; Anthony R Hayward; Suk See DeRavin; Ottavia M Delmonte; Michael E Grigg; Adam Kerry Dobbs; Julie E Niemela; Jennifer Stoddard; Zaid Alhinai; Natasha Rybak; Nancy Hernandez; Stefania Pittaluga; Sergio D Rosenzweig; Gulbu Uzel; Luigi D Notarangelo
Journal:  Front Immunol       Date:  2019-02-14       Impact factor: 7.561
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.